IL22 and hepatocellular carcinoma: Therefore, in future multi-center clinical studies should be performed to explore the prognostic significance of IL-22 expression in HCC patients treated with sorafenib and its correlation with the expressions of STAT3 and CD155 in the tumor tissues collected from those patients to validate our conclusion.